By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
AdkhabarAdkhabarAdkhabar
Notification Show More
Font ResizerAa
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Reading: DLH to Announce Fiscal 2025 Fourth Quarter Financial Results
Share
Font ResizerAa
AdkhabarAdkhabar
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Search
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Follow US
Adkhabar > Blog > Health > DLH to Announce Fiscal 2025 Fourth Quarter Financial Results
DLH to Announce Fiscal 2025 Fourth Quarter Financial Results
Health

DLH to Announce Fiscal 2025 Fourth Quarter Financial Results

GlobeNews Wire
Last updated: 21/11/2025 1:38 AM
GlobeNews Wire
Published: 21/11/2025
Share
SHARE

November 20, 2025 13:37 ET  | Source: DLH Holdings Corp.

ATLANTA, Nov. 20, 2025 (GLOBE NEWSWIRE) — DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of science research and development, systems engineering and integration, and digital transformation and cyber security solutions to federal agencies, will release financial results for the fiscal fourth quarter ended September 30, 2025 on December 10, 2025 after the market closes. DLH will then host a conference call for the investment community at 10:00 a.m. Eastern Time the following day, December 11, 2025, during which members of senior management will make a brief presentation focused on the financial results and operating trends. A question-and-answer session will follow.  

Interested parties may listen to the conference call by dialing 888-347-5290 or 412-317-5256.  Presentation materials will also be posted on the Investor Relations section of the DLH website prior to the commencement of the conference call. A digital recording of the conference call will be available for replay two hours after the completion of the call and can be accessed on the DLH Investor Relations website or by dialing 1-855-669-9658 and entering the conference ID 7526746.
  
About DLH
DLH (NASDAQ: DLHC) enhances technology, public health, and cyber security readiness missions through science, technology, cyber, and engineering solutions and services. Our experts solve some of the most complex and critical missions faced by customers today, leveraging digital transformation, artificial intelligence, advanced analytics, cloud-based applications, telehealth systems, and more. With over 2,400 employees dedicated to the idea that “Your Mission is Our Passion,” DLH brings a unique combination of technology, innovation, and world-class expertise, to improve lives across the globe. For more information, visit www.DLHcorp.com.

INVESTOR RELATIONS
Contact: Chris Witty
Phone: 646-438-9385
Email: cwitty@darrowir.com

NYSE Content Advisory: Pre-Market Update + Evommune Rises in Trading Debut
Knot.dating Opens Doors for IAS, IPS, IRS; Private Sector Entry Requires 50L+ Salary
Vor Bio to Participate in the Stifel2025 Virtual Immunology and Inflammation Forum
Carbon Clean accelerates carbon capture with launch of Global Innovation Centre in India
Terns Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London
TAGGED:2025announcedlhfinancialfiscalfourthNasdaq:DLHCnewsquarterresultsUS23335Q1004
Share This Article
Facebook Email Print
- Advertisement -

Follow US

Find US on Social Medias
FacebookLike
XFollow
YoutubeSubscribe

Weekly Newsletter

Subscribe to our newsletter to get our newest articles instantly!
Popular News

Automobili Lamborghini brings Italian artistry to Miami Beach with a uniquely designed Temerario during Art Basel Miami 2025

TheNews Market
TheNews Market
04/12/2025
Sidetrade joins the Euronext Tech Leaders 2025
QCI Expands Leadership Depth with Strategic Hires with the VizExplorer Integration
Canara HSBC Life Insurance signs Indian cricket icon Jasprit Bumrah and celebrated sports presenter Sanjana Ganesan as brand ambassadors
Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjgrens disease
- Advertisement -
- Advertisement -
- Advertisement -

Categories

  • Automobile
  • Entertainment
  • E-Sports
  • Food
  • Health
  • Technology
  • LifeStyle
  • Travel

About Us

Through our news networks, we raise millions of users' awareness. We are among the world's most reputable news networks.
Quick Link
Top Categories
  • Entertainment

Subscribe US

Subscribe to our newsletter to get our newest articles instantly!

AdkhabarAdkhabar
Copyright © 2021 - 2025 AdKhabar. All Rights Reserved. POWERED BY Life Care News.
Join Us!
Subscribe to our newsletter and never miss our latest news, podcasts etc..
Zero spam, Unsubscribe at any time.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?